Systematic "Adherence Intervention" Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Raltegravir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms THILAO
- 31 Aug 2018 Biomarkers information updated
- 31 Aug 2017 New trial record
- 26 Jul 2017 Results assessing virological outcomes at 48 weeks (W48) for patients who initiated third-line therapy, presented at the 9th International AIDS Society Conference on HIV Science.